This is the authors' abstract. We don't add key points for this paper.
Mycophenolate mofetil was superior to azathioprine in maintaining a renal response to treatment and in preventing relapse in patients with lupus nephritis who had a response to induction therapy. (Funded by Vifor Pharma [formerly Aspreva]; ALMS ClinicalTrials.gov number, NCT00377637.).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dooley et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: